Compare Repligen Corporation Common Stock (RGEN) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Tapestry, Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Tapestry, Inc. trades at $115.03 (market cap $22.87B). The key difference: Tapestry, Inc. is far larger — about 2.1× Repligen Corporation Common Stock's market cap, and Tapestry, Inc. pays a 1.61% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Tapestry, Inc. for 70 Days on average.
| RGEN | TPR | |
|---|---|---|
Market Cap | $11.14B | $22.87B |
Volume | 1,259,263 | 1,963,570 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $164.78 |
52-Week Low | $102.87 | $98.81 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $11.02B | $25.67B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TPR trades at $115.03, down 1.87% today, with a neutral technical signal and bearish moving averages. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined to $183M. Recent earnings beats and a $174.64 consensus price target suggest upside potential. International growth in China and Europe supports fiscal 2027 expansion plans.
Outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and 52% upside to price target. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation at 15.85 P/E. Strong cash flow generation and Coach brand momentum provide fundamental support despite recent price weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
